Thomas Brandt
Cardiovascular Disease · Council Bluffs, IANPI 1992746416
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,924 and has fallen 85.9% since, to $270 in 2022.
Across 154 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$389
- E.r. Squibb & Sons, L.L.C.$290
- Amgen$272
- Johnson & Johnson$228
- Novartis$179
- Medtronic$177
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,604100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 19 | $389 |
| E.r. Squibb & Sons, L.L.C. | 17 | $290 |
| Amgen | 20 | $272 |
| Johnson & Johnson | 19 | $228 |
| Novartis | 17 | $179 |
| Medtronic | 2 | $177 |
| Abbott | 2 | $155 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $128 |
| Novo Nordisk | 7 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $91 |
| Boston Scientific | 4 | $84 |
| Gilead | 5 | $64 |
| Actelion Pharmaceuticals US, Inc. | 4 | $58 |
| Amarin Pharma, Inc. | 3 | $38 |
| Merck | 3 | $38 |
| Seagen Inc. | 2 | $38 |
| Servier Pharmaceuticals LLC | 2 | $37 |
| AstraZeneca | 2 | $35 |
| Eisai Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Boehringer Ingelheim | 2 | $28 |
| Biolase, Inc. | 1 | $18 |
| Aegerion Pharmaceuticals, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
| Electromed, Inc. | 1 | $12 |
| Cardiovascular Systems Inc. | 1 | $11 |
| Lundbeck LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$363
- CoreValve Evolut$155
- CardioMEMS HF System$130
How this compares
$2,604 in reported general payments places this provider in the 70th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Council Bluffs
- Joseph AyoubCouncil Bluffs$19K
- Terrence SlatteryCouncil Bluffs$4K
- Anand DeshmukhCouncil Bluffs$3K
- Brian OlshanskyIowa City$219K
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Gursukhman Deep SidhuDavenport$60K
- Suzanne FeigofskyWest Des Moines$59K
- Tyler RasmussenCedar Rapids$37K
- Jennifer RobinsonIowa City$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.